Literature DB >> 11174380

CD2- CD4+ CD56+ hematodermic/hematolymphoid malignancy.

N Kato1, K Yasukawa, K Kimura, H Sugawara, S Aoyagi, T Mishina, T Nakata.   

Abstract

BACKGROUND: CD2- CD4+ CD56+ lymphoid malignancy has been only rarely reported the last 5 years. It is characterized by a high incidence of cutaneous involvement, cytologically agranular cells, aggressive clinical course, and negative Epstein-Barr virus (EBV) involvement. OBSERVATION: We describe a Japanese patient with a unique hematolymphoid malignancy characterized by an involvement of skin, nasopharyngeal region, bone marrow, lymph node, and a CD4+ CD43+ CD56+ CD2- CD3- CD8- and terminal deoxynucleotidyl transferase phenotype. Clinically, the cutaneous eruptions were purplish, hard, multiple nodules. Histologically, a massive proliferation of atypical pleomorphic cells with medium-sized nuclei were observed throughout the dermis. No clonal rearrangement of T-cell receptor (TCR)-beta gene or immunoglobulin heavy chain J gene was found, and no positive identification of EBV by in situ hybridization for EBV-encoded small nuclear RNA was found. The patient underwent high-dose chemotherapy with autografting of peripheral blood stem cells; however, the tumors quickly relapsed.
CONCLUSION: We gathered data from 17 cases of lymphoid malignancy from the literature sharing immunophenotypic and genotypic features similar to those of our case, including CD2- CD4+ CD56+ and germline rearrangement of TCR. Although the cellular origin could not be decided, this malignancy was found to have 100% affinity for skin, a short course, and poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11174380     DOI: 10.1067/mjd.2001.110897

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

1.  Central nervous system involvement in CD4+/CD56+ hematodermic neoplasm: a report of two cases.

Authors:  Nóra Eros; Márta Marschalkó; Katalin Balassa; Bernadett Hídvégi; József Szakonyi; Sándor Ilniczky; Katalin Borka; Attila Kovács; Gyula Bottlik; Judit Hársing; Judit Csomor; Agota Szepesi; András Matolcsy; Sarolta Kárpáti; Judit Demeter
Journal:  J Neurooncol       Date:  2009-10-02       Impact factor: 4.130

2.  CD4-/CD56+/CD123+ Hematodermic Neoplasm Showing Early Liver Metastasis.

Authors:  Kyu-Won Choi; Ki-Yeol Lee; Yeong-Kyu Lee; Bon-Seok Ku; Hong-Seok Kim; Young-Hun Kim; Ki-Ho Kim
Journal:  Ann Dermatol       Date:  2010-05-18       Impact factor: 1.444

3.  Case for diagnosis.

Authors:  Paula Maio; Candida Fernandes; Ana Afonso; Fernanda Sachse; José Cabeçadas; Jorge Cardoso
Journal:  An Bras Dermatol       Date:  2013 Jan-Feb       Impact factor: 1.896

Review 4.  What is CD4+CD56+ malignancy and how should it be treated?

Authors:  P Reimer; T Rüdiger; D Kraemer; V Kunzmann; F Weissinger; A Zettl; H Konrad Müller-Hermelink; M Wilhelm
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.